Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic
  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Sickle Cell Disease Treatment Market to Exhibit a CAGR of 18.5% and Reach USD 7.71 Billion by 2027; FDA Approval for Emmaus’s Endari to Aid Development, states Fortune Business Insights™

Pune, India, Jan. 20, 2021 (GLOBE NEWSWIRE) -- The global sickle cell disease treatment market size is expected to reach USD 7.71 billion in 2027, exhibiting a CAGR of 18.5% during the forecast period. The unmet needs of patients and lack of novel therapies has resulted in research grants from governments, which, in turn, will promote the growth of the market, states Fortune Business Insights, in a report, titled “Sickle Cell Disease Treatment Market Size, Share & Covid-19 Impact Analysis, By Treatment Modality (Bone Marrow Transplant, Blood Transfusion, Pharmacotherapy (Hydroxyurea and Branded Drugs (Endari, Adakveo, Oxbryta, Zynteglo, CTX001, Mitapivat, and FT-4202))), By End User (Hospitals, Specialty Clinics, and Others), and Regional Forecast, 2020-2027.” The market size stood at USD 1.35 billion in 2019.

The entire world is fighting with the COVID-19 pandemic, which has severely disrupted trades across the globe. The authorities of several countries have initiated lockdown to prevent the spread of this deadly virus. Such plans have caused disturbances in the production and supply chain. But, with time and resolution, we will be able to combat this stern time and get back to normality. Our well-revised reports will help companies receive in-depth information about every market's present scenario so that you can adopt the necessary strategies accordingly.


Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/sickle-cell-disease-treatment-market-101009


The sickle cell disease treatment market highpoints a comprehensive study of the market. It also offers essential facts about prominent players, besides revealing data about central regions in the market. The report includes key drivers and trends prevailing in the industry. Significant development, along with COVID’s impact, is covered in the study.

FDA Product Approval to Intensify Business

The introduction of innovative drugs and therapies to treat sickle cell diseases can spur lucrative opportunities for the market. For instance, in 2017, FDA approved Emmaus Life Sciences product Endari to treat patients with sickle cell disease aged five years and older. Moreover, the approval of three products by the regulatory bodies such as the FDA and EMA will foster the market's healthy growth. For instance, Oxbryta (Global Blood Therapeutics), Adakveo (Novartis AG), and Endari (Emmaus Life Sciences) are being utilized in the treatment of the disease. Oxbryta has been approved ahead of its statutory deadline. Moreover, products such as Zynteglo, CTX001, Mitapivat, and FT-4202 are expected to receive approval in the forthcoming years, which, in turn, will enable speedy expansion of the market. For instance, CTX001 has been granted EMA’s priority medicines (PRIME) designation in Europe.


To get to know more about the short-term and long-term impacts of COVID-19 on this market, please visit:  https://www.fortunebusinessinsights.com/industry-reports/sickle-cell-disease-treatment-market-101009


Postponement of Surgeries to Diminish Product Demand Amid Coronavirus

Delay in non-urgent surgeries has resulted in a major drop in the number of BMT and blood transfusion procedures. The pandemic severely affected the demand and blood donor base. Moreover, lockdown and travel restrictions have led to a decline in the number of donors and the cancellation of numerous blood drives worldwide. For instance, U.S. blood centers witnessed a 30% decline in blood drives scheduled for the rest of the year, leading to about 250,000 missed donations. Furthermore, according to American Red Cross Blood Services, more than 50,000 blood drives have been canceled or moved due to the pandemic. These aforementioned factors reveal the enormous loss encountered by the sickle cell disease treatment industry during the coronavirus.

Novartis AG to Dominate the Market

Novartis AG accounted for the maximum share in the global market. The company entered the market with the approval of Adakveo in 2019. The drug can reduce the sickle cell pain crises by 45% in the clinical trials and hence is. Therefore, increasing demand for Adakveo among patients is expected to reinforce the company’s position.


Quick Buy -  Sickle Cell Disease Treatment Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/101009


Strong Government Support to Support Growth in the U.S.

The U.S market size stood at USD 0.71 billion in 2019 and is expected to remain dominant during the forecast period. The growth in the region is attributed to improving access to SCD treatment and potential pipeline candidates. The strong government support in the U.S. will further foster the healthy development of the market. According to the Center for International Blood and Marrow Transplant Research, in 2017, 157 hematopoietic cell transplants were performed in 2017 in the U.S for SCD. The number of BMT increased by 35.3% during 2013-2017. These factors together are expected to favor growth in the region.

Key Development:

September 2020: Global Blood Therapeutics, Inc. signed an exclusive agreement with Biopharma-MEA to distribute Oxbryta in Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates.


The Report Lists the Key Players in the Sickle Cell Disease Treatment Market:

  • Novartis AG (Basel, Switzerland)
  • Global Blood Therapeutics Inc. (California, U.S.)
  • Emmaus Medical Inc. (California, U.S.)
  • Addmedica (Paris, France)
  • Medunik USA Inc. (Pennsylvania, U.S.)
  • Bristol-Myers Squibb Company (New York City, U.S.)
  • Other prominent players


Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/sickle-cell-disease-treatment-market-101009


Table of Contents:

  • Introduction
    • Research Scope
    • Market Segmentation
    • Research Methodology
    • Definitions and Assumptions
  • Executive Summary
  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Key Insights
    • Overview of Sickle Cell Disease Treatment Services
    • Reimbursement Scenario – For Key Countries/ Regions
    • Overview of Sickle Cell Disease Treatment Policies – For Key Countries
    • Technological Advancements in Sickle Cell Disease Treatment
    • State of Telehealth Adoption – For Key Countries/ Regions
    • Major Sickle Cell Disease Treatment Service Providers – For Key Countries
    • Internet Users & Penetrations Statistics
    • Growth in Usage of Telehealth Technology Among Physicians
    • Key Industry Developments - Mergers, Acquisitions and Partnerships
    • Impact of COVID-19 on Sickle Cell Disease Treatment Market
  • Global Sickle Cell Disease Treatment Market Analysis, Insights and Forecast, 2016-2027
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast – By Treatment Modality
      • Bone Marrow Transplant
      • Blood Transfusion
      • Pharmacotherapy
        • Hydroxyurea
        • Branded Drugs
          • Endari
          • Adakveo
          • Oxbryta
          • Zyntelgo
          • CTX001
          • Mitapivat
          • FT-4202
    • Market Analysis, Insights and Forecast – By End User
      • Hospitals
      • Specialty Clinics
      • Others
    • Market Analysis, Insights and Forecast – By Geography
      • U.S.
      • Europe
      • Rest of World


TOC Continued….!


Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/sickle-cell-disease-treatment-market-101009


SECONDARY RESEARCH IS CONDUCTED TO DERIVE THE FOLLOWING INFORMATION:

  • Details such as revenues, market share, strategies, growth rate, product & their pricing by region/country for all major companies
  • Details in relation to prevalence, incidence, patient numbers, distribution of patients, average price of treatment, etc.
  • Number of end user facilities by region/country and average annual spending or procurement of devices by type of end user facility
  • Number of procedures and average price of procedures
  • Replacement rate and pricing of capital equipment
  • Market dynamics in relation to the market under focus – Drivers, restraints, trends, and opportunities
  • Market & technological trends, new product developments, product pipeline.


Have a Look at Related Reports:

Deep Brain Stimulation (DBS) Devices Market Share & Industry Analysis, By Product Type (Dual Channel Deep Brain stimulators, Single Channel Deep Brain Stimulators), By Application (Parkinson's Disease, Dystonia, Essential Tremor, Others), By End User (Hospitals, Specialty Clinics, Others) and Regional Forecast, 2019-2026

Biomarkers Market Share & Industry Analysis, By Indication (Oncology, Cardiology, Neurology, and Others), By End User (Pharmaceutical & Biotechnology Companies, Diagnostics & Research Laboratories, Hospitals & Specialty Clinics, and Others), and Regional Forecast, 2019-2026

Neuroendoscopy Devices Market Share & Industry Analysis, By Product Type (Rigid Neuroendoscopes, Flexible Neuroendoscopes), By Application Type (Transnasal Neuroendoscopy, Intraventricular Neuroendoscopy, Transcranial Neuroendoscopy), By End User (Hospitals, Specialty Clinics, Others) and Regional Forecast, 2019-2026

Ophthalmic Diagnostic Devices Market Share & Industry Analysis, By Product Type (Optical Coherence Tomography, Aberrometer & Topography Systems, Fundus Camera, Ophthalmic Ultrasound, and Other Ophthalmic Devices), By End-user (Hospitals, Ophthalmic Clinics, Others), and Regional Forecast, 2019-2026

Internet of Medical Things (IoMT) Market Share & Industry Analysis, By Product Type (Stationary Medical Devices, Implanted Medical Devices, Wearable External Medical Devices), By Application (Telemedicine, Medication Management, Patient Monitoring, Others), By End User (Healthcare Providers, Patients, Government Authorities, Others) and Regional Forecast, 2019-2026


About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.


Contact Us:

Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.

Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Fortune Business Insights™
LinkedIn | Twitter | Blogs


Press Release: https://www.fortunebusinessinsights.com/press-release/global-sickle-cell-disease-treatment-market-10464


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.